Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › GUTS

Fractyl Health

GUTS Lead: Phase 3 ★ Read the deep dive → 9 Biotech Distilled articles ↓
Metabolic Gene Therapy

Most recent annual filing: 2026-01-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Rejuva readout2H 2026Rejuva readout, 2H 2026, notable
  2. RJVA-001 corporate update2H 2026RJVA-001 corporate update, 2H 2026, routine
  3. Corporate guidance updateSep 2026Corporate guidance update, Sep 2026, routine
  4. Nasdaq listing updateSep 2026Nasdaq listing update, Sep 2026, routine
  5. Revita pivotal topline4Q 2026Revita pivotal topline, 4Q 2026, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Technology platforms

Rejuva

AAV-delivered pancreatic gene therapy platform designed to enable long-term remission of T2D and obesity by durably reprogramming pancreatic islet cells to endogenously produce metabolic hormones (GLP-1, GIP, PYY, amylin, glucagon). Modular platform using AAV9 vectors with tissue-restricted insulin promoter-driven transgene expression, delivered via proprietary endoscopic device directly to the pancreas.

Targets: GLP-1, GIP, PYY, amylin

Discontinued (1)

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.